Abstract: Tyrosine kinase inhibitor (TKI) therapy has revolutionized the therapy of chronic myeloid leukemia (CML). Thus, while in the near past allogeneic transplantation was the curative option for CML, imatinib, nilotinib, and dasatinib have pushed transplantation to the role of salvage therapy in CML. Still, TKI therapy still fails some patients, and so the clinical challenge is to integrate transplantation in a safe and sane manner. This manuscript reviews the data on the variables that have an influence on outcome following transplantation, and discusses the variables to consider in determining who and when patients should receive transplantation.
Introduction
Prior to the tyrosine kinase inhibitor (TKI) revolution, allogeneic transplantation was the treatment of choice for chronic myeloid leukemia (CML). While transplantation is still considered to be the only 'curative' therapy for CML, it is associated with an appreciable cost of morbidity and mortality, which is considered unacceptable compared with the outcomes of patients in chronic phase treated with TKI therapy. Nonetheless, outcomes with allogeneic transplant are remarkable in the 'modern era', at least in the chronic phase of the disease. The issue then is distilled into the 'who/ when/why' categories of recommendations.
Summary of outcomes with TKI therapy
To place allogeneic transplantation in the proper context, it is useful to summarize what we know about the effectiveness of TKI therapy.
1. Primary therapy for chronic phase CML is highly effective, and roughly 80% of cases will at some point achieve a complete cytogenetic remission (CCyR). For these patients, survival at 8þ years is nearly 90%. 2. However, in clinical trials, TKI therapy will fail in approximately 30% of cases due to drug intolerance, primary resistance, relapse, or progression to advanced phase disease. There is some data suggesting these rates may be higher in the real-world setting of community practice. 3. Initial therapy with the 'second-generation' TKIs (nilotinib, dasatinib) appears to be more effective than imatinib in early (12-month) endpoints of CCyR and molecular response. There is no advantage to overall survival (OS) yet, and obviously long-term complications are unknown. 4. For patients receiving therapy with secondgeneration TKIs for resistant disease, approximately 50% will achieve a CCyR. The survival for these patients is 80% at 3 years. Those who do not achieve and maintain a CCyR often relapse and harbor new Abl kinase domain mutations. 5. Patients with accelerated phase (AP) or blast crisis (BC) phase can occasionally achieve a CCyR with TKI therapy, but relapse generally occurs quickly, often with a resistant Abl kinase mutation. 6. Patients who have a T315I mutation do not respond to currently available TKI therapy. As natural selection would dictate, selection of this mutation increases as patients become resistant to more and more TKIs.
Given the findings noted above, the obvious niche for transplantation becomes restricted to chronic phase patients intolerant to all TKIs (rare), patients who are resistant to imatinib mesylate and secondgeneration therapy, patients with T315I mutations, and cases of advanced phase disease (AP or BC).
What results can transplantation offer?
Allogeneic transplantation results
The results of allogeneic stem cell transplantation have improved over time given the wholesale changes involving infectious disease prophylaxis and therapy, a more complete appreciation of the human leukocyte antigen (HLA) systems, improvements of graft versus host disease (GVHD) prophylaxis and therapy, advances in preparative regimens, etc.
Multiple factors have been found to have an influence on survival following transplantation. In summary, however, survival is >80% for chronic phase patients, 4050% for advanced phase patients, and 20% for BC patients. For patients in BC placed back into remission, results are similar to advanced phase.
Phase of disease
The strongest determinant of any therapy for CML is the phase of disease. For chronic phase CML, the Seattle, German consortium, and Hammersmith teams report remarkably consistent 5-year survival rates of 8590% ( Figure 1 ) [Saussele et al. 2010; Radich et al. 2003 ]. The Seattle experience, using targeted busulfan (BU) and cytoxan in matched related transplants showed a 3-year survival of 86%, a relapse rate of 8%, and nonrelapse mortality (NMR) rate of 14% [Radich et al. 2003 ]. In addition, 90% of the survivors were in molecular remission at last contact.
Outcomes in advanced phase disease are far inferior to chronic phase, and have not notably improved over time, unlike chronic phase results [Devergie et al. 1990; Martin et al. 1988] . Outcomes in AP are approximately half of those of chronic phase, with survival and event-free survival of 50% and 40%, respectively [Clift et al. 1994] . The results for patients in BC are very poor, due to both relapse and transplant-related deaths, with 35-year survival only 1020% [Goldman et al. 1988; Thomas et al. 1986] . Data from the Fred Hutchinson Cancer Research Center from 1995 to the present are shown in Figure 2 , demonstrating the effect of phase on survival.
Patient age
Initial studies of transplantation for CML demonstrated a strong age effect, with younger patients far better than older patients [Thomas et al. 1986] . However, the effect of age does not appear to be as strong in more recent data, although it is impossible to determine whether this is accounted for by patient selection, and/or the advances transplantation and supportive care [Clift et al. 1993 ]. Age appears to play a more important role in the unrelated donor (URD) setting, likely from the influence of GVHD [Hansen et al. 1998 ].
Donor type
For cases without a matched related donor, a majority of cases can find a matched URD from the world donor registries. Advances in HLA typing and GVHD therapy has made marked improvements in transplant outcomes. For many diseases, including CML, results with a fully matched URD are quite similar to that achieved with a matched related donor [Davies et al. 2001; Hansen et al. 1998 ]. In general, related transplants have less nonrelapse mortality (NRM) (from GVHD and associated complications, mainly infectious) compared with unrelated transplants, while having more relapses (due to less graft versus leukemia effect). The limited data with syngeneic transplants suggests that graft versus leukemia (GVL) is an important modality in curing CML, as relapse rates are considerably higher than in HLA-matched related transplants [Fefer et al. 1979] . However, a longterm follow up of 22 twin transplants [Fefer et al. 1982] suggests that the high-dose preparative regimen is sometimes sufficient to eradicate CML, as after 20 years of follow up, 7/12 chronic phase patients are alive posttransplant, and 5 have maintained their initial posttransplant complete remission (unpublished data courtesy of Dr Alex Fefer and Dr Ted Gooley).
Time from diagnosis to transplant
Several studies demonstrate an impact on time to transplant from initial diagnosis and outcome [Enright et al. 1996; Goldman et al. 1993] . For example, the International Bone Marrow Transplant Registry (IBMTR) in 2002 reported that from 19941999 the long-term (>5-year) survival of chronic phase patients was 70% for cases transplanted in chronic phase within the first year from diagnosis, and 60% for patients transplanted >1 year from diagnosis (see http:// www.ibmtr.org). IBMTR data suggested that exposure to low-dose BU led to a worse outcome with subsequent transplantation [Goldman et al. 1993] . In addition, several reports suggested that exposure to interferon (IFN) might worsen the outcome of URD transplant, though the effect on matched sibling transplantation were unclear. In a report of 856 patients randomized to hydroxyurea, BU, or IFN, 197 went on to transplant. The 5-year survival from transplant was only 46% for patients who received IFN within the last 90 days before transplant, as opposed to 71% for those who did not (p ¼ 0.0057) [Hehlmann et al. 1999] .
Fortunately, prior therapy with imatinib does not appear to have an influence on transplant outcomes. While early reports warned of an increase in regimen-related toxicity and mortality, especially from hepatic causes [Shimoni et al. 2003 ], subsequent larger studies do not demonstrate an effect of pretransplant imatinib [Oehler et al. 2007; Deininger et al. 2006; Zaucha et al. 2005] .
In fact, an IBMTR study of 409 patients who received imatinib therapy transplant compared with 900 cases that did not suggested that those chronic phase patients who received imatinib had an improved outcome following transplant, although this effect seemed to be limited in cases who moved to transplantation because they could not tolerate imatinib, rather than treatment failure [Lee et al. 2008] . There was no positive or negative effect of imatinib in the outcome of advanced phase patients.
Source of hematopoietic stem cells Two large randomized trials involving patients with a variety of hematologic malignancies demonstrated that use of granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSCs), compared with bone marrow, lead to faster myeloid and platelet recovery, no significant difference in acute or chronic GVHD and an OS advantage. In these studies there was a trend towards improved survival in CML patients with the use of peripheral blood [Couban et al. 2002; Bensinger et al. 2001] . A randomized study of chronic phase CML showed no statistically significant differences in outcome between the bone marrow and peripheral blood groups. Relapse rates were lower in the peripheral blood group, but chronic GVHD was higher in cases that received PBSCs [Oehler et al. 2005] . PBSCs are thus a preferred choice for advanced phase disease; in chronic phase, the tradeoff between relapse and GVHD must be considered.
Reduced intensity conditioning in CML Reduced intensity conditioning (RIC) or nonmyeloablative (NMA) transplants are based on the immunological GVL effect, and they have provided a successful treatment option for many hematological malignancies. The experience of RIC and NMA transplantation in CML is limited due to the success of TKI therapy, and the subsequent shift in transplant populations to those patients with more resistant or progressive disease, where the use of a stronger, fully ablative preparative regimen is generally advisable. Two small reports of NMA using a preparative regiment of Flu/TBI or 2 Gy TBI showed a high rejection rate, but a low NRM rate of <5%, with survival of >70% [Kerbauy et al. 2005; Or et al. 2003 ]. The EBMT group reported results on 186 patients with CML (median age 50 years) who received RIC [Crawley et al. 2005] , and found 100-day NRM of 6%, 2-year NRM of 23%, and a 3-year OS and relapse-free survival (RFS) of 58% and 37%, respectively. Over 60% of patients enjoyed a complete cytogenetic remission, while 40% attained a complete molecular response by polymerase chain reaction (PCR) testing. These studies suggest that RIC/NMA transplantation is a promising approach for CML patients, and one can imagine a combined approach to target leukemic stem cells utilizing a lower intensity transplantation followed by TKI prophylaxis.
Prognostic scoring systems
Pretransplant variables can define a prognostic scoring system for transplantation in CML. The system devised by Gratwohl and colleagues uses HLA matching, stage, age, sex of donor/recipient, and time from diagnosis to transplant [Gratwohl et al. 1998 ]. The scoring system is effective in defining posttransplant outcomes following an ablative transplant, with survival in European bone marrow transplant (EBMT) data of 70% for the best (lowest) score to 20% for the worst (highest) score (Figure 3 ). This scoring was recently applied again to EBMT cases transplanted in three cohorts, 19801990, 19911999, and 20002002 [Gratwohl et al. 2006] . In all risk groups, OS has improved over the chronological era. However, given that transplantation is being reserved for cases of TKI failure and/or advanced phase disease, the value of this prognostic scoring system is largely for patient information rather than decisionmaking. Table 1 suggests a more current prognostic scheme under various scenarios where transplantation should be considered.
Rationale for transplantation
Front-line therapy TKI therapy has clearly, and logically, replaced transplantation as front-line therapy. It is hard to imagine conditions where a trial of TKI would not be initially performed in newly diagnosed chronic phase patients. The exception might be in rare regions/countries where TKI therapy is not available, or cost concerns force health agencies to elect transplantation as a potentially curative therapy, rather than a lifetime of expensive TKI therapy. There have been a few attempts to compare upfront transplantation with nontransplant therapy [Hehlmann et al. 2007] . One trial enrolled 621 patients with chronic phase CML. Of this set, only 354 patients were eligible for transplantation and 'biologically randomized' based on the availability of a related donor. Of the 123 patients who received a transplant, the 10-year estimate of survival was 53% (surprisingly low given other data from this group) Therapeutic Advances in Hematology 1 (1) [Saussele et al. 2010] . Those 219 patients without a related donor were treated with IFN until imatinib became available later in the trial. Imatinib was then offered to patients with a poor response to IFN. The 10-year estimate of survival in this group was 52%. The survival curves of these two groups show that the transplant group suffered a higher early mortality, with a flattening of the survival curves thereafter. The nontransplant group had a better early outcome, but the survival curves continued to drop over the history of the trial. The 'cross-over' point of the curves (favoring transplantation) came at 8 years. There are several issues that make this study difficult to interpret in the 2010s, however. The 'nontransplant' group contained patients who underwent an URD transplant; the survival in the URD transplant group was better than all other groups (69%). Moreover, both the transplant group and the IFN/Imatinib group had outcomes worse than anticipated. As one cannot imagine a randomized study occurring with up-front TKI use versus transplant, it seems prudent to unreservedly recommend imatinib (or second-generation TKI) as initial therapy of chronic phase CML. However, in health systems where a TKI cannot be obtained (due to financial limitations or other bureaucratic/infrastructure restrictions), then transplant would be a good option for initial therapy of chronic phase disease .
Chronic phase, intolerance or resistance Intolerance to primary TKI therapy is unusual, but if it occurs, generally another TKI can be employed effectively, since 'cross-intolerance' is unusual. There are rare patients who cannot tolerate any TKI without toxicity, and those cases are properly considered for transplantation.
Resistance occurs in 2030% of chronic phase cases treated with imatinib, and less (to date) in cases treated initially with nilotinib or dasatinib. For cases that become resistant to imatinib, a second-generation TKI restores or elicits CCyR Kantarjian et al. 2007 Kantarjian et al. , 2006 . Moreover, patients who do fail secondary therapy often have a new mutation [Hughes et al. 2009; Muller et al. 2009; Soverini et al. 2009] . Molecular data has shown that the biological states of resistance and progression have a large overlap [McWeeney et al. 2010; Oehler et al. 2009; Radich et al. 2006] and, thus, persistent poor response may be a prequel to progression to advanced phase disease.
Patients who fail to respond to salvage therapy, or who relapse after therapy, are obvious candidates for transplantation. However, how long should clinicians treat a case before changing course towards transplantation? Efforts have been made to identify clinical or laboratory variables that will predict outcome after the initiation of secondary TKI therapy. At present, early cytogenetic response to a secondary TKI seems to predict long-term response. Thus, patients who are placed on a secondary TKI, but who fail to have any cytogenetic response after 3 months of therapy appear unlikely to ever achieve a CCyR. Likewise, failure to achieve at least a minor cytogenetic response by 6 months, or a MCyR by 12 months of secondary therapy bodes poorly for sustained disease control [Tam et al. 2008] . Given that one must allow months to judge a potential response, it is imperative to begin HLA testing of families and, if needed, URDs while the trial of salvage therapy is ongoing. Since progression is always a concern in patients who become resistant to front-line therapy, once salvage therapy is begun, the clock is ticking: if the second-generation drug is ineffective, unopposed BCR-ABL activity is setting the stage for progression.
T315I mutations
If a patient has relapsed on imatinib with a T315I mutation, it seems reasonable to proceed to transplant, given the lack of meaningful response to approved secondary TKI therapy. Likewise, those who have a mutation within the P loop region, which seem in many studies to be associated with an increased risk of progression to advance phase disease, transplant may seem a reasonable option as well despite better odds of response to a secondary TKI.
Advanced phase disease AP and BC phase disease are generally poorly and briefly responsive to TKI therapy. Thus, patients who present with advanced phase disease, or progress to advanced phase disease, should be offered transplantation. Note that the results of allogeneic matched, unrelated, and umbilical cord transplants are quite similar under current protocols, so most patients can find a potential donor. Since the logistics leading up to the actual transplant may take weeks to months, patients with advanced phase disease should receive therapy prior to transplant. For cases who have progressed through TKI therapy, this might encompass conventional chemotherapy and/or novel therapeutics; for those patients who present de novo in advanced stage disease, an approved TKI, with or without chemotherapy, should be used.
TKI therapy after transplant
Relapse is the main cause of treatment failure after an allogeneic transplant. If relapse is defined at a molecular (PCR) level, some patients may never progress, or at least may not progress for a very long time [Radich et al. 2001 . Cytogenetic relapse is generally the reason for therapeutic intervention posttransplant. An increasing number of potential interventions are available to the patient who has relapsed after allogeneic transplantation for CML. Treatment with IFN can produce both clinical and cytogenetic remissions in patients who have relapsed after transplantation [Higano et al. 1997] . Results with IFN appear better if treatment is initiated at the time of cytogenetic relapse instead of waiting until hematologic relapse. However, early treatment of relapse in CML has been supplanted by imatinib [Kantarjian et al. 2002; Olavarria et al. 2002] . The response to imatinib correlates with the stage of disease at transplant. Complete hematological response was seen in >90% of chronic phase cases, >50% of AP, and >20% of BC cases. A complete cytogenetic remission was accomplished in >40% of cases, higher in chronic phase than advanced phase disease. Also, imatinib appears to be effective in the prophylactic setting in order to prevent relapse in high-risk Phþ disease (Phþ ALL and blast crisis CML) [Carpenter et al. 2007] . In a study by the Seattle group, 22 patients (15 with Phþ ALL, 7 with CML) were given imatinib at a median of 28 days postengraftment; in all but one case patients tolerated imatinib at the targeted dose (400 mg/day for adults, 260 mg/m 2 /day for children). In total 19 patients completed a year of posttransplant therapy, and at a median of roughly one and a half years, 5/7 of the CML patients and 12/15 of the Phþ ALL cases were in a molecular remission.
Conclusion
In CML clinicians are blessed with several effective modalities of therapy, and relatively easy monitoring techniques that serve as surrogates for clinical outcome. The clinical challenge is to employ monitoring, secondary therapy, and transplantation in an order that prevents escalation to advanced phase disease, where all modalities are relatively dismal compared with chronic phase disease. For patients with chronic phase disease, TKI should be the first choice; careful monitoring will discover those patients needing secondary therapy. The choice of therapy can be made based on the presence of an Abl mutation (especially what type), and the early response of secondary therapy, if applied. For patients with advanced phase disease, transplantation is the option of choice, although therapy with a TKI while the transplant is being arranged is recommended if possible.
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